Creative Medical Technology Holdings Inc (NASDAQ: CELZ) is a clinical-stage biotechnology company developing stem cell and cell therapy treatments for degenerative and metabolic diseases. The company generates no commercial revenue as of its fiscal year ended December 31, 2025, funding operations through equity offerings, including a Securities Purchase Agreement with Roth Capital Partners as placement agent (October 2024) and inducement letters executed in March 2025 and October 2025. Its principal programs are StemSpine (AlloStem, CELZ-201-DDT), a Phase 1/2 trial targeting chronic back pain from degenerative disc disease, and CELZ-201, a cell therapy in clinical trials for prevention of Type 1 Diabetes in high-risk individuals. In February 2025, the company entered an expanded collaboration with Greenstone Biosciences to apply AI-driven drug discovery to its human induced pluripotent stem cell (iPSC) platform for diabetes treatment. Headquartered in the Phoenix, Arizona area (area code 480), the company has been audited by Haynie and Company since 2016. It carries an accumulated deficit and operates at a net loss, as reflected in its consolidated statements of operations for the years ended December 31, 2025 and 2024.

Revenue model

No commercial revenue disclosed in the filing excerpts. Operations are financed through equity issuances, including common stock and warrant sales and Series B preferred stock offerings.

Products and services

StemSpine (AlloStem, CELZ-201-DDT): allogeneic stem cell therapy in Phase 1/2 clinical trial for chronic back pain due to degenerative disc disease; FDA-cleared expanded dose escalation announced March 2025. CELZ-201: cell therapy for prevention of Type 1 Diabetes in high-risk individuals; FDA expanded access authorization secured March 2024. iPSC-derived pancreatic islet cell platform: human induced pluripotent stem cells producing human insulin, with AI collaboration with Greenstone Biosciences announced February 2025.

Customers and end markets

Clinical-stage; no commercial customers disclosed. End markets are degenerative disc disease and Type 1 Diabetes prevention. Clinical trial participants constitute the current patient population.

Value-chain role

Drug developer and clinical-stage sponsor. Relies on contract research organizations (CROs), academic institutions, and corporate partners for clinical trial execution and research activities. Patent assets acquired via related-party purchase obligation.

Geographic exposure

Headquartered in the Phoenix, Arizona area. Filing references foreign jurisdiction regulatory risk, but no specific international revenue or operations are quantified in the excerpts.

Source: SEC 10-K, filed 2026-03-20

Industry: Biological Products, (No Diagnostic Substances) Peers: Acorda Therapeutics, Inc. Aditxt Inc Panbela Therapeutics, Inc. CONTRAFECT Corp NUTRA PHARMA CORP MANHATTAN SCIENTIFICS INC Revelation Biosciences Inc Dogwood Therapeutics Inc